• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.链激酶治疗心肌梗死后的中和抗体：一个持续存在的谜题。
Br Heart J. 1995 Aug;74(2):122-3. doi: 10.1136/hrt.74.2.122.
2
Clinical usefulness of a functional test of neutralising streptokinase antibodies for the prediction of the thrombolytic effect of streptokinase in acute myocardial infarction.用于预测链激酶在急性心肌梗死中溶栓效果的中和链激酶抗体功能试验的临床实用性。
Cardiology. 2003;100(1):36-40. doi: 10.1159/000072390.
3
Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction.
J Intern Med. 1999 May;245(5):483-8. doi: 10.1046/j.1365-2796.1999.00485.x.
4
The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction.链激酶中和抗体对急性心肌梗死患者链激酶治疗后纤溶活性及再灌注的影响
J Intern Med. 2002 Nov;252(5):405-11. doi: 10.1046/j.1365-2796.2002.01049.x.
5
[Anti-streptokinase antibodies].[抗链激酶抗体]
Arch Mal Coeur Vaiss. 1997 Jul;90(7):975-80.
6
Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment?抗链激酶抗体能否预测链激酶治疗后的心肌梗死结局？
J Pak Med Assoc. 2012 Mar;62(3 Suppl 2):S31-4.
7
Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).链激酶诱发的低血压对急性心肌梗死溶栓治疗的患者没有不利影响。罗马尼亚急性心肌梗死加速链激酶研究（ASK-ROMANIA）的一项子研究。
Rom J Intern Med. 2004;42(3):557-73.
8
Anti-streptokinase titers and response to streptokinase treatment in Pakistani patients.
Int J Cardiol. 2002 Mar;82(3):247-51. doi: 10.1016/s0167-5273(02)00004-9.
9
Effect of pretreatment antistreptokinase antibody and streptococcal infection on the efficacy and dosage of streptokinase in acute myocardial infarction.预处理抗链激酶抗体及链球菌感染对急性心肌梗死患者链激酶疗效和剂量的影响
Saudi Med J. 2005 Jun;26(6):934-6.
10
Thrombolysis with recombinant streptokinase in Cuba.古巴使用重组链激酶进行溶栓治疗。
BMJ. 2003 Feb 22;326(7386):448. doi: 10.1136/bmj.326.7386.448/a.

引用本文的文献

1
Antibodies to streptokinase.抗链激酶抗体。
BMJ. 1996 Feb 17;312(7028):393-4. doi: 10.1136/bmj.312.7028.393.

本文引用的文献

1
THE LABORATORY CONTROL OF THROMBOLYTIC THERAPY.溶栓治疗的实验室控制
J Clin Pathol. 1964 May;17(3):287-91. doi: 10.1136/jcp.17.3.287.
2
Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy.
Am J Cardiol. 1993 Mar 15;71(8):640-5. doi: 10.1016/0002-9149(93)91003-z.
3
Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction.
Am J Cardiol. 1993 Aug 15;72(5):462-4. doi: 10.1016/0002-9149(93)91143-6.
4
Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres.
Eur Heart J. 1993 Dec;14(12):1640-3. doi: 10.1093/eurheartj/14.12.1640.
5
Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.急性心肌梗死静脉注射链激酶后长达866天的链激酶中和效价。
Br Heart J. 1993 Aug;70(2):119-21. doi: 10.1136/hrt.70.2.119.
6
Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.急性心肌梗死后重复溶栓治疗的安全性和有效性。
Br Heart J. 1990 Sep;64(3):177-81. doi: 10.1136/hrt.64.3.177.
7
Streptokinase resistance: when might streptokinase administration be ineffective?链激酶抵抗：何时使用链激酶可能无效？
Br Heart J. 1992 Nov;68(5):449-53. doi: 10.1136/hrt.68.11.449.
8
Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.对急性心肌梗死患者在给予链激酶或阿尼普酶后长达30个月的链激酶抗性滴度进行监测，以及进行相关研究以测定特异性抗链激酶IgG。
Br Heart J. 1992 Aug;68(2):167-70. doi: 10.1136/hrt.68.8.167.

链激酶治疗心肌梗死后的中和抗体：一个持续存在的谜题。

Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.

作者信息

McGrath K, Hogan C, Hunt D, O'Malley C, Green N, Dauer R, Dalli A

机构信息

Department of Diagnostic Haematology, Royal Melbourne Hospital, Parkville, Australia.

出版信息

Br Heart J. 1995 Aug;74(2):122-3. doi: 10.1136/hrt.74.2.122.

DOI:10.1136/hrt.74.2.122
PMID:7546988
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC483985/
Abstract

OBJECTIVE

To determine the development of titres of streptokinase (SK) neutralising antibodies after a single dose of SK, to establish when titres decrease to levels at which a second dose might be effective.

DESIGN

Analyses of blood samples taken from patients at intervals after SK administration.

SETTING

Australian public hospital.

PATIENTS

104 patients with acute myocardial infarction who were treated with SK and 27 controls who were not.

OUTCOME MEASURE

SK neutralising antibodies were measured once in each of the 27 controls and on 166 occasions in the 104 treated patients.

RESULTS

Titres of SK neutralising antibodies rose after SK administration but returned to control levels by 2 years.

CONCLUSIONS

SK might be effective again as a thrombolytic agent as early as 2 years after a single dose. These results are at variance with most previously published data and the reasons for this are not clear. Data evaluating patency rates after standard doses of streptokinase in patients with increased titres of neutralising antibodies are necessary before re-exposure to streptokinase can be recommended.

摘要

目的

确定单次注射链激酶（SK）后SK中和抗体滴度的变化情况，以确定滴度何时降至第二次注射可能有效的水平。

设计

对SK给药后不同时间间隔采集的患者血样进行分析。

地点

澳大利亚公立医院。

患者

104例接受SK治疗的急性心肌梗死患者和27例未接受治疗的对照者。

观察指标

对27例对照者各检测1次SK中和抗体，对104例接受治疗的患者检测166次。

结果

SK给药后SK中和抗体滴度升高，但2年后恢复至对照水平。

结论

单次注射SK后最早2年，SK可能再次作为溶栓剂有效。这些结果与之前大多数已发表的数据不同，原因尚不清楚。在推荐再次使用链激酶之前，有必要评估中和抗体滴度升高的患者使用标准剂量链激酶后的血管通畅率数据。